Please assess the completion status of the following clinical trial:

Trial Title: Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male gender~2. Age ≥18 years and ≤45 years~3. BMI ≥16~4. P. falciparum parasitaemia at any density~5. G6PD deficiency by Beutler Fluorescent Spot test for intervention groups and control group receiving AL only (N=50)~6. G6PD normal activity by Beutler Fluorescent Spot test for control groups (N=20)~7. Informed consent by participant~Exclusion Criteria:~1. Enrolled in another clinical trial~2. Fever \>37.5°C (tympanic) or history of fever in the last 24 hours~3. Evidence of severe illness / danger signs or active infection other than malaria~4. Known allergy to study medications~5. Hb \<11 g/dL~6. Antimalarials taken within the last 2 weeks~7. PQ taken within the last 4 weeks and blood transfusion within the last 90 days~8. Non-falciparum malaria co-infection~9. Current use of tuberculosis or anti-retroviral medication, sulphonamides, dapsone, nitrofurantoin, , nalidixic acid, ciprofloxacin, , methylene blue, toluidine blue phenazopyridine and co-trimoxazole.~10. History of severe chronic illness

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- G6PD deficient 0.25 mg/kg PQ + AL (Type: EXPERIMENTAL): G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
- G6PD deficient receiving AL only (Type: ACTIVE_COMPARATOR): G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
- G6PD normal 0.25 mg/kg PQ + AL (Type: ACTIVE_COMPARATOR): G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
- G6PD normal 0.4 mg/kg PQ + AL (Type: ACTIVE_COMPARATOR): G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
- G6PD-deficient 0.4 mg/kg PQ + AL (Type: EXPERIMENTAL): G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).